Evidence map›Paper›PMID 36978002›Full record

ArticleBMC neurology2023

Efficacy and safety of decompressive craniectomy in acute ischemic stroke patients treated with intravenous thrombolysis.

Elyar Sadeghi-Hokmabadi, Farhad Mirzaei, Mohammad Yazdchi, Javad Jalili, Yalda Sadeghpour, Behzad Nemati-Anari, Mehdi Farhoudi, Pouneh HamianRoumiani

Open access · goldFull text read
In one paragraph

Article in BMC neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Elyar Sadeghi-HokmabadiNeurosciences Research Center (NSRC), Department of Neurology, Imam-Reza hospital, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0002-5481-6027
Farhad MirzaeiDepartment of Neurosurgery, Imam-Reza hospital, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0003-0560-3110
Mohammad YazdchiDepartment of Neurology, Imam-Reza hospital, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0002-5469-3709
Javad JaliliInterventional Radiology, Department of Radiology, Imam-Reza hospital, Tabriz University of Medical Sciences, Tabriz, Iran. javadjalili1979@gmail.com.ORCID https://orcid.org/0000-0003-0588-2287
Yalda SadeghpourNeurosciences Research Center (NSRC), Department of Neurology, Imam-Reza hospital, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0003-4939-9895
Behzad Nemati-AnariDepartment of Neurology, Imam-Reza hospital, Ardebil University of Medical Sciences, Ardebil, Iran.ORCID https://orcid.org/0000-0002-8422-4743
Mehdi FarhoudiNeurosciences Research Center (NSRC), Department of Neurology, Imam-Reza hospital, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0002-4972-9316
Pouneh HamianRoumianiNeurosciences Research Center (NSRC), Department of Neurology, Imam-Reza hospital, Tabriz University of Medical Sciences, Tabriz, Iran.
Tabriz University of Medical Sciences · IRArdabil University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe optimal timing for decompressive hemicraniectomy (DHC) after intravenous thrombolysis (IVT) remains unclear. This study in patients with acute ischemic stroke treated with IVT aimed to assess the safety of DHC and patient outcome.

methodsData was extracted from the Tabriz stroke registry from June 2011 up to September 2020. In all, 881 patients were treated with IVT. Among these, 23 patients underwent DH. Six patients were excluded due to symptomatic intracranial hemorrhage (parenchymal hematoma type 2 based on SITS-MOST definition) after IVT, but other types of bleeding after venous thrombolysis, including HI1, HI2, and PH1 were not excluded; so the remaining 17 patients were enrolled in the study. Functional Outcome was defined as the proportion of patients who achieved mRS score of 2-3 (moderate disability), 4-5 (severe disability), or 6 (mortality) at 90 days after stroke. mRSwas assess by trained neurologist at the hospital clinic with direct interview Safety outcome was assessed by comparison of two scans just prior to and after craniectomy. Any new hemorrhage or worsening of previous hemorrhage was reported. Parenchymal hematoma type 2, based on ECASS II definition, was considered as major surgical complication. This study was approved by the local ethics committee of the Tabriz University of Medical Sciences (Ethics Code: IR.TBZMED.REC.1398.420).

resultsAt the three-month mRS follow up, six patients (35%) had moderate and five (29%) had severe disability. The outcome of death was observed in six patients (35%).Nine of 15 patients (60%) underwent surgery in the first 48 hours after onset of symptoms. No patient over 60 years of age survived to the three-month follow up; 67% of those who were under60 years and underwent DH in the first 48 hours had favorable outcome. Hemorrhagic complication was seen in 64% of patients but none was major.

conclusionResults of this study showed that the rate of major bleeding and outcome of acute ischemic stroke patients who underwent DHC after IVT is comparable with the reported data in the literature and intentionally waiting for the fibrinolytic effects of IVT to disappear may not outweigh the benefits of DHC. Although the findings of the study should be interpreted with caution and larger studies are needed to confirm the results.

Indexed as

Brain IschemiaDecompressive CraniectomyIschemic StrokeStrokeAgedFibrinolytic AgentsHematomaHumansIntracranial HemorrhagesMiddle AgedThrombolytic TherapyTissue Plasminogen ActivatorTreatment OutcomeFibrinolytic AgentsTissue Plasminogen ActivatorDecompressive craniectomyIschemic strokeModified Rankin scaleTissue plasminogen activator

Identifiers

PMID36978002
PMCPMC10045929
OpenAlexW4361216928

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read44
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.